Signature Equity Partners’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
Other funds holding AZN
EP
IA
Signature Equity Partners's AZN Position: Q2 2026 in Review
Signature Equity Partners reduced its AstraZeneca (AZN) stake by 3.2% in Q2 2026, selling an estimated $1.69K and leaving 270 shares worth $51.2K. The position accounts for 0.02% of the portfolio, ranked #422.
Signature Equity Partners first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. The position peaked at $55.1K in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Signature Equity Partners held 270 shares of AstraZeneca worth $51.2K as of Q2 2026.
- Signature Equity Partners sold 9 AstraZeneca shares in Q2 2026, an estimated $1.69K.
- AstraZeneca made up 0.02% of Signature Equity Partners's portfolio in Q2 2026, its #422 holding.
- Signature Equity Partners first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
- Signature Equity Partners's AstraZeneca position peaked at $55.1K in Q1 2026.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.